Unlike the HAWK and HARRIER studies which reported the incidence of retinal vasculitis with retinal vascular occlusion 2.1%, it was recently reported to be 4.6 per 10,000 injections in the post-marketing surveillance.[28] This difference might be due to difference in recruited population who were treatment naïve in the phase-III clinical trial, since patients who were previously treated with anti-VEGF drugs were more susceptible to IOI. This evidence concerns the gene VEGFA and retinal vasculitis.